A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects
2019 ◽
Vol 57
(03)
◽
pp. 167-174
◽
Keyword(s):
Phase I
◽
2017 ◽
Vol 79
(5)
◽
pp. 881-888
◽
Keyword(s):
2011 ◽
Vol 69
(1)
◽
pp. 221-227
◽
2020 ◽
Vol 85
(5)
◽
pp. 995-1001
◽
2009 ◽
Vol 38
(1)
◽
pp. 3-11